Peramivir appears to be a promising new antiviral in the armamentarium against influenza and has already received FDA emergency-use authorization for the treatment of severe pandemic H1N1 influenza. Its intravenous formulation makes it particularly attractive for treating severely ill patients, but dose-finding trials have not yet been completed in this population. Animal studies indicate that multiple doses of peramivir for up to 15 days might be appropriate for such patients.
Journal Watch. 2010;30(24) © 2010 Massachusetts Medical Society
Cite this: Treatment of Influenza with Intravenous Peramivir - Medscape - Dec 15, 2010.